Clinical-stage biotechnology company PYC Therapeutics (ASX:PYC) has announced a leadership transition, with Chair Alan Tribe appointed as Managing Director following the resignation of Dr Rohan Hockings, who has served as Chief Executive Officer and Executive Director since 2018.
Dr Hockings has provided two months' notice and is expected to leave the company by 16 November 2025.
Mr Tribe, who joined the Board in 2018, brings extensive corporate and commercial experience and has worked closely with the executive team over several years. He will now be based in Perth full-time, assuming responsibility for Investor Relations and Business Development, while leading the company’s ongoing drug development programs.
The Board has commenced a search for a permanent Managing Director. In the interim, Mr Tribe has already met with leadership teams across PYC’s four clinical programs to ensure they remain on track in line with timelines and budgets. The company confirmed that the Polycystic Kidney Disease program remains a priority, with updates on progress to be provided in due course.
Mr Tribe said, “I would like to thank Rohan for his significant contributions to the Company and wish him well in the future. There will now be a robust search to select a successor who can lead the future growth and development of the Company for its shareholders.”
PYC Therapeutics is pioneering a new generation of RNA-based precision medicines, targeting monogenic diseases with high potential for clinical success. The company’s proprietary delivery platform is designed to significantly enhance the potency of RNA therapies, positioning PYC as a leader in the rapidly expanding RNA therapeutics field.